secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001628280-24-034976
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q2 revenue up 10.3% (organic +13.9%); raises FY2024 guidance
----------------------------------------------------------------------

- Revenue $151.2M (+10.3% YoY); Pain Treatments +17.2%, Surgical Solutions +18.6% US.
- Net loss from continuing operations $32.1M vs $4.7M, including $31.9M impairment and litigation settlement.
- Adjusted EBITDA $34.5M (+22.4% YoY); non-GAAP EPS $0.19 vs $0.14.
- Raising FY2024 guidance: revenue $557-567M, adjusted EBITDA $104-107M, non-GAAP EPS $0.36-0.42.
- FDA clearance for OSTEOAMP Cannula; pursuing divestiture of Advanced Rehabilitation to reduce debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024034976/0001628280-24-034976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024034976/bvs-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-034976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer